100 new jobs are to be added at West Pharmaceuticals in Dublin over the next five years, following a 60,000 sq ft expansion.
West also revealed that its contract manufacturing business – formerly known as The Tech Group – will now align with the West brand.
West is a contract manufacturer for the medical device industry and a global leader in solutions for injectable drug administration, especially in the area of diabetes.
‘Ireland has seen hundreds of millions invested in recent years in the development and manufacturing of new injectable drugs for diabetes, cardiovascular disease, autoimmune disease and cancer’
– MARTIN SHANAHAN
As well as expanding its injectable products manufacturing capacity in Dublin, West is also building a new pharmaceutical component manufacturing facility.
West anticipates 100 new jobs will be added to the business over the next five years as a result of the expansion.
Centre of excellence
“As the healthcare market becomes increasingly complex, West is advancing our core competencies in the development, manufacturing and final packaging of complex drug delivery systems and diagnostic devices for our customers,” said Karen Flynn, senior vice president and chief commercial officer at West.
“We are excited about the growth and expansion we are experiencing in both our contract manufacturing business in Dublin, as well as our proprietary products business in Waterford, both of which will support increasing demand from our global customer base.”
Along with the expansion of its Dublin facility, West is also growing its proprietary product business in Waterford, Ireland.
The company previously announced the construction of a centre of excellence for its proprietary elastomeric sheeting and injectable component product lines. The new plant is expected to begin full commercial operations in 2018.
“With this most recent expansion in Dublin and the company’s previously announced investment in Waterford, West is affirming its presence as an important employer in Ireland,” said Jobs Minister Mary Mitchell O’Connor, TD.
IDA Ireland’s life sciences sector continues to grow from strength to strength, said CEO Martin Shanahan.
“This investment by West is a good example of the potential for convergence across the life sciences sector,” he explained.
“Ireland has seen hundreds of millions invested in recent years in the development and manufacturing of new injectable drugs for diabetes, cardiovascular disease, autoimmune disease and cancer. The patients who will benefit from these exciting new drugs will also benefit from West’s innovation in drug delivery devices.”
Looking for jobs in tech or science? Check out our Employer Profiles for information on companies hiring right now and sign up for our Career Republic e-zine for a weekly digest of sci-tech careers news and advice.
